Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20878372 | 0.95 | CYP3A4 (0.47) | CYP3A4CYP2C9BTN3A1RIPK1POLRMT | |
| SCHEMBL19223082 | 0.95 | CYP3A4 (0.47) | CYP3A4CYP2C9BTN3A1RIPK1POLRMT | |
| SCHEMBL18636591 | 0.95 | CYP3A4 (0.47) | CYP3A4CYP2C9BTN3A1RIPK1POLRMT | |
| SCHEMBL24975049 | 0.93 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL25012467 | 0.93 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL18636485 | 0.93 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL18636597 | 0.92 | CYP3A4 (0.41) | CYP3A4CYP2C9BTN3A1RIPK1POLRMT | |
| SCHEMBL20078684 | 0.92 | CYP3A4 (0.41) | CYP3A4CYP2C9BTN3A1RIPK1POLRMT | |
| SCHEMBL20878382 | 0.91 | CYP3A4 (0.39) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL18667331 | 0.91 | CYP3A4 (0.39) | CYP3A4CYP2C9BTN3A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885BTN3A1 4160/4885 |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885BTN3A1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.